Adverse effects (during study) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Economic outcomes · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Total mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in all‐cause mortalitya compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Strokea · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in strokea compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Any bleedingb · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in any bleedingb compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Adverse events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thromboembolic events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in any thromboembolic event compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Major bleeding · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in major bleeding compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Mortality Median · patients with primary CNS lymphoma
Cytarabine plus high‐dose methotrexate showed no clear difference in mortality (median 3 years) compared with high‐dose methotrexate alone (moderate certainty).
1 finding from 1 review
Progression/relapse · patients with primary CNS lymphoma
Cytarabine plus high‐dose methotrexate probably leads to lower progression/relapse (median 3 years) compared with high‐dose methotrexate alone (moderate certainty).
1 finding from 1 review
Treatment‐related mortality · patients with primary CNS lymphoma
Cytarabine plus high‐dose methotrexate showed no clear difference in treatment‐related mortality compared with high‐dose methotrexate alone (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with primary CNS lymphoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe adverse effects (grade 3+): Infection · patients with primary CNS lymphoma
Cytarabine plus high‐dose methotrexate probably leads to higher infections (grade 3 to 4) compared with high‐dose methotrexate alone (moderate certainty).
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · children and young adults with CF
1 finding from 1 review
FVC (% predicted) Change from baseline · children and young adults with CF
1 finding from 1 review
Height velocity (cm/year) · children and young adults with CF
1 finding from 1 review
Change in weight (kg) · children and young adults with CF
1 finding from 1 review
QoL · children and young adults with CF
1 finding from 1 review
Fasting blood glucose (mg/dL) · children and young adults with CF
1 finding from 1 review